← 返回

CD8+ T 细胞空间生物标志物在 ER+和 ER-乳腺癌中的预后意义:一项回顾性队列研究

英文原题:Prognostic significance of CD8+ T cell Spatial Biomarkers in ER+ and ER- breast cancer: A retrospective cohort study.

查看英文原题

Prognostic significance of CD8+ T cell Spatial Biomarkers in ER+ and ER- breast cancer: A retrospective cohort study.

PubMed 2025/10/15(内容时间) PLoS Med Q1 · IF 9.9(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

研究概要

由邻近性和一致性描述的空间特征经常与复发相关,且与 ER 状态无关。邻近性在 ER+乳腺癌中的预后意义提示,空间参数可能识别出可从免疫治疗中获益的个体;高达 75% 的乳腺癌存在提示免疫易感性的 T 细胞邻近性。

研究思路结论见上方概要

TIL(肿瘤浸润淋巴细胞)(TILs)在三阴性乳腺癌中具有预后意义,但在占乳腺癌70%-80%的雌激素受体(ER)阳性癌症中则不然。这是由于ER阳性肿瘤中免疫浸润相对较低。然而,很少有研究利用空间方法评估较低丰度TILs的预后影响。本研究的目的是探讨淋巴细胞相对于肿瘤细胞的分布是否能预测预后。方法与发现:在这项回顾性队列研究中,我们使用来自1,467名研究参与者的组织微阵列核心的多重免疫荧光(IF)染色图像(染色针对细胞角蛋白[Ck]、CD8和FoxP3),计算上皮细胞和免疫细胞基于距离的视觉形态计量学,包括两个新指标:邻近性和一致性。邻近性和一致性被定义为Ck+肿瘤细胞与CD8+ T细胞之间最近邻距离的均值和方差的函数。通过Kaplan-Meier生存曲线差异的log-rank检验和Cox比例风险模型,将邻近性和一致性的预后意义与淋巴细胞计数进行比较。在CD8+ T细胞高邻近性和高一致性的ER+和ER-乳腺癌中,均观察到更好的无复发生存期(RFS)。在ER-乳腺癌中,与计数和一致性相比,邻近性具有最高的RFS风险比(HR 1.84,95% CI [1.18, 2.87];p = 0.0069)。在ER阳性参与者中,邻近性和一致性的RFS风险比分别为2.04(95% CI [1.39, 2.98];p = 0.0003)和1.82(95% CI [1.23, 2.69];p = 0.0026)。这些关联强于淋巴细胞计数所观察到的关联(HR 1.35,95% CI [0.92, 1.98];p = 0.1289)。通过控制年龄、肿瘤分级、分期、ER状态、孕激素受体状态和人表皮生长因子受体2状态等临床和人口统计学变量,证明了其独立的预后价值。这些IF衍生的空间指标也与已建立的TILs指标和基于RNA表达的肿瘤适应性免疫反应测量相关。尽管这些结果令人鼓舞,但我们对肿瘤免疫微环境的探索受限于可用于我们数据的免疫标志物数量较少。

展开英文摘要原文

Tumor infiltrating lymphocytes (TILs) are prognostic in triple-negative breast cancer, but not estrogen receptor (ER) positive cancers which comprise 70%-80% of breast cancers. This is due to the relatively low immune infiltration in ER-positive tumors. However, few studies have explored the prognostic impact of lower abundance TILs evaluated using spatial methods. The objective of this study was to explore whether the distribution of lymphocytes with respect to tumor cells predicts prognosis. METHODS AND FINDINGS: In this retrospective cohort study, we used multiplex immunofluorescent (IF)-stained images of tissue microarray cores (stained for cytokeratin [Ck], CD8, and FoxP3) obtained from 1,467 study participants to compute distance-based visual morphometry for epithelial and immune cells, including two new metrics, proximity and consistency. Proximity and consistency are defined as functions of the mean and variance of nearest neighbor distances between Ck+ tumor cells and CD8+ T cells. Prognostic significance of proximity and consistency were compared to lymphocyte counts using log-rank tests of differences in Kaplan-Meier survival curves and Cox proportional hazards models. Better recurrence-free survival (RFS) was observed for both ER+ and ER- breast cancers with high proximity and consistency of CD8+ T cells. Among ER- breast cancers, proximity had the highest RFS hazard ratio (HR 1.84, 95% CI [1.18, 2.87]; p = 0.0069) compared to count and consistency. Among ER-positive participants, RFS hazard ratios for proximity and consistency were 2.04 (95% CI [1.39, 2.98]; p = 0.0003) and 1.82 (95% CI [1.23, 2.69]; p = 0.0026), respectively. These associations were stronger than those observed for lymphocyte count (HR 1.35, 95% CI [0.92, 1.98]; p = 0.1289). Independent prognostic value was demonstrated by controlling clinical and demographic variables such as age, tumor grade, stage, ER status, progesterone receptor status, and human epidermal growth factor receptor 2 status. These IF-derived spatial metrics were also associated with established TILs metrics and RNA expression-based measures of tumor adaptive immune response. Though these results are promising, our exploration of the tumor immune microenvironment was limited by the small number of immune markers available for our data.

Spatial characteristics described by proximity and consistency are frequently associated with recurrence irrespective of ER status. The prognostic significance of proximity in ER+ breast cancer implies that spatial parameters may identify individuals who would benefit from immune therapy; up to 75% of breast cancers experience T cell proximity suggestive of immune susceptibility.

论文信息

作者
Walker AE、Gao X、Wang Q、De la Cruz G、Li D、Perou CM、Saltz J、Marron JS
第一作者单位
Department of Statistics and Operations Research, University of North Carolina, Chapel Hill, North Carolina, United States of America.United States
通讯作者单位
UNC Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina, United States of America.United States
期刊
PLoS medicine2025 Oct
原文标识
PubMed 41091832 · DOI 10.1371/journal.pmed.1004647